Clearside reports Q2 loss of $7.8M, secures $65M non-dilutive financing, OASIS data due Nov

Clearside Biomedical, Inc.

2023-Q2 EPS reported -$0.26 revenue$731,000

Net loss $7.8M ($0.13/shr) vs $6.1M ($0.11/shr) in Q2 2021; license revenue $384K down from $780K.
Cash $29.0M at June 30; initial $32.5M royalty payment from HealthCare Royalty extends runway into 2024.
CLS-AX OASIS Phase 1/2a top-line data for all four cohorts expected November 2022.
Non-dilutive financing up to $65M: $32.5M initial, $12.5M escrow, $20M milestone upon XIPERE sales targets.
Appointed Susan L. Coultas, Ph.D., as Chief Clinical Officer; XIPERE J-code effective July 1, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.